600216 浙江医药
已收盘 05-07 15:00:00
资讯
新帖
简况
浙江医药新提交“子午金”、“岭上丹”等4件商标注册申请
证券之星 · 04-30
浙江医药新提交“子午金”、“岭上丹”等4件商标注册申请
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
浙江医药（600216）2026年一季报简析：净利润同比下降29.84%
证券之星 · 04-25
浙江医药（600216）2026年一季报简析：净利润同比下降29.84%
浙江医药最新公告：第一季度净利润同比下降29.84%
证券之星 · 04-23
浙江医药最新公告：第一季度净利润同比下降29.84%
浙江医药(600216)3月31日股东户数5.18万户，较上期减少15.77%
证券之星 · 04-11
浙江医药(600216)3月31日股东户数5.18万户，较上期减少15.77%
浙江医药(600216.SH)发布2025年度业绩，归母净利润8.73亿元，同比下降24.74%
智通财经 · 04-10
浙江医药(600216.SH)发布2025年度业绩，归母净利润8.73亿元，同比下降24.74%
浙江医药最新公告：拟分拆子公司新码生物至港交所主板上市
证券之星 · 04-10
浙江医药最新公告：拟分拆子公司新码生物至港交所主板上市
浙江医药（600216）披露与私募基金合作投资进展公告，4月7日股价上涨3.87%
证券之星 · 04-07
浙江医药（600216）披露与私募基金合作投资进展公告，4月7日股价上涨3.87%
每周股票复盘：浙江医药（600216）股东拟减持不超1%股份
证券之星 · 03-22
每周股票复盘：浙江医药（600216）股东拟减持不超1%股份
浙江医药最新公告：股东国投高科拟减持不超1%股份
证券之星 · 03-16
浙江医药最新公告：股东国投高科拟减持不超1%股份
每周股票复盘：浙江医药（600216）拟投1.57亿参与生物医药基金
证券之星 · 03-15
每周股票复盘：浙江医药（600216）拟投1.57亿参与生物医药基金
浙江医药（600216）披露与私募基金合作投资公告，3月9日股价下跌4.03%
证券之星 · 03-09
浙江医药（600216）披露与私募基金合作投资公告，3月9日股价下跌4.03%
浙江医药最新公告：以1.57亿元自有资金认缴出资成为厦门华犇启航股权投资合伙企业有限合伙人
证券之星 · 03-09
浙江医药最新公告：以1.57亿元自有资金认缴出资成为厦门华犇启航股权投资合伙企业有限合伙人
每周股票复盘：浙江医药（600216）新码生物获6.2亿增资并推进ARX305 II期临床
证券之星 · 03-08
每周股票复盘：浙江医药（600216）新码生物获6.2亿增资并推进ARX305 II期临床
3月6日浙江医药涨7.86%，长信医疗LOF基金重仓该股
证券之星 · 03-06
3月6日浙江医药涨7.86%，长信医疗LOF基金重仓该股
浙江医药（600216）披露ARX305启动II期临床试验公告，3月5日股价上涨0.77%
证券之星 · 03-05
浙江医药（600216）披露ARX305启动II期临床试验公告，3月5日股价上涨0.77%
浙江医药(600216.SH)：ARX305启动II期临床试验
智通财经 · 03-05
浙江医药(600216.SH)：ARX305启动II期临床试验
浙江医药最新公告：子公司新码生物拟实施C轮增资并引入六名战略投资者
证券之星 · 03-03
浙江医药最新公告：子公司新码生物拟实施C轮增资并引入六名战略投资者
每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金
证券之星 · 03-01
每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金
浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%
证券之星 · 02-24
浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%
公司概况
公司名称：
浙江医药股份有限公司
所属行业：
医药制造业
上市日期：
1999-10-21
主营业务：
浙江医药股份有限公司的主营业务是药品与生命营养品的研发、生产和销售以及药品流通。公司的主要产品是维生素、类维生素产品、抗耐药抗生素、抗疟疾类、喹诺酮、抗耐药抗生素、降糖类、激素类、叶黄素、天然维生素E、辅酶Q10、医药商业。公司入选首批浙江省制造业单项冠军企业、浙江省第一批先进级智能工厂。
发行价格：
5.16
{"stockData":{"symbol":"600216","market":"SH","secType":"STK","nameCN":"浙江医药","latestPrice":14.21,"timestamp":1778137200000,"preClose":14.33,"halted":0,"volume":16008170,"delay":0,"changeRate":-0.0084,"floatShares":951000000,"shares":961999999,"eps":0.7813,"marketStatus":"已收盘","change":-0.12,"latestTime":"05-07 15:00:00","open":14.33,"high":14.33,"low":14.09,"amount":227000000,"amplitude":0.0167,"askPrice":14.22,"askSize":299,"bidPrice":14.21,"bidSize":2581,"shortable":0,"etf":0,"ttmEps":0.7813,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778203800000},"marketStatusCode":5,"adr":0,"adjPreClose":14.33,"symbolType":"stock","openAndCloseTimeList":[[1778117400000,1778124600000],[1778130000000,1778137200000]],"highLimit":15.76,"lowLimit":12.9,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":961637750,"isCdr":false,"pbRate":1.22,"roa":"--","peRate":18.187636,"roe":"2.59%","epsLYR":0.91,"committee":0.19053,"marketValue":13665000000,"turnoverRate":0.0168,"status":1,"floatMarketCap":13519000000},"requestUrl":"/m/hq/s/600216/wiki","defaultTab":"wiki","newsList":[{"id":"2631457984","title":"浙江医药新提交“子午金”、“岭上丹”等4件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2631457984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631457984?lang=zh_cn&edition=full","pubTime":"2026-04-30 08:39","pubTimestamp":1777509558,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日浙江医药股份有限公司新提交“子午金”、“岭上丹”等4件商标注册申请。商标申请详情如下：今年以来浙江医药股份有限公司新申请注册商标4件，截止目前公司共持有注册商标370件，另有6件商标尚在注册申请中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000030196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0028","BK0188","BK0239","600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0132","BK0191","BK0183","BK0250","300723","600216","06978","LU2328871848.SGD","BK0188","301281","BK0175","BK1574","002550","000963","BK0028","BK0209","BK0239","BK0187","688621","BK0216","BK0071","688117","LU1969619763.USD","BK1161","BK0196","000950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630878420","title":"浙江医药（600216）2026年一季报简析：净利润同比下降29.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630878420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630878420?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:06","pubTimestamp":1777068364,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期浙江医药发布2026年一季报。根据财报显示，浙江医药净利润同比下降29.84%。截至本报告期末，公司营业总收入21.91亿元，同比下降2.86%，归母净利润2.87亿元，同比下降29.84%。持有浙江医药最多的基金为天弘医疗健康混合A，目前规模为2.6亿元，最新净值1.6999，较上一交易日上涨0.72%，近一年下跌6.15%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500019704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629152881","title":"浙江医药最新公告：第一季度净利润同比下降29.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629152881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629152881?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:22","pubTimestamp":1776936176,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，2026年第一季度实现营业收入21.91亿元，同比下降2.86%；归属于上市公司股东的净利润为2.87亿元，同比下降29.84%。业绩变动主要系公司主要产品维生素E、维生素A系列产品销售价格同比去年一季度下降所致。注：公司Q1净利润2.87亿，2025年Q4净利润-0.6亿，据此计算，Q1净利润环比扭亏为盈。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300047431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626287351","title":"浙江医药(600216)3月31日股东户数5.18万户，较上期减少15.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626287351","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626287351?lang=zh_cn&edition=full","pubTime":"2026-04-11 17:02","pubTimestamp":1775898145,"startTime":"0","endTime":"0","summary":"证券之星消息，近日浙江医药披露，截至2026年3月31日公司股东户数为5.18万户，较12月31日减少9705.0户，减幅为15.77%。在化学制药行业个股中，浙江医药股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.45万户。从股价来看，2025年12月31日至2026年3月31日，浙江医药区间涨幅为15.95%，在此期间股东户数减少9705.0户，减幅为15.77%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041100013005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0191","600216","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626190072","title":"浙江医药(600216.SH)发布2025年度业绩，归母净利润8.73亿元，同比下降24.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626190072","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626190072?lang=zh_cn&edition=full","pubTime":"2026-04-10 20:54","pubTimestamp":1775825642,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浙江医药(600216.SH)披露2025年年度报告，报告期公司实现营收88.81亿元，同比下降5.28%;归母净利润8.73亿元，同比下降24.74%;扣非净利润8.34亿元，同比下降28.10%;基本每股收益0.91元。公司拟向全体股东每股派发现金红利0.28元(含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427304.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626199236","title":"浙江医药最新公告：拟分拆子公司新码生物至港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2626199236","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626199236?lang=zh_cn&edition=full","pubTime":"2026-04-10 18:10","pubTimestamp":1775815834,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，公司披露关于分拆所属子公司浙江新码生物医药股份有限公司至香港联合交易所有限公司主板上市的预案。本次分拆完成后，浙江医药预计仍将维持对新码生物的控制权，新码生物财务状况和盈利能力仍体现在公司合并报表中。新码生物主营创新生物药研发，核心管线包括ADC药物ARX788等。此次分拆旨在理顺业务架构，释放创新药板块估值潜力，拓宽融资渠道，提升综合竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000033071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600216","BK0028","HEXmain","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625593219","title":"浙江医药（600216）披露与私募基金合作投资进展公告，4月7日股价上涨3.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625593219","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625593219?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:10","pubTimestamp":1775571029,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，浙江医药报收于16.37元，较前一交易日上涨3.87%，最新总市值为157.42亿元。近日，浙江医药股份有限公司披露《与私募基金合作投资进展公告》。公告显示，公司于2026年2月24日与多家机构签署合伙协议，作为有限合伙人认缴出资2.5亿元参与投资廊坊信慧银发经济股权投资基金合伙企业，占其认缴总额的31.25%。截至2026年4月8日，公司累计对外投资金额达4.07亿元，包括对厦门华犇启航股权投资合伙企业的投资。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700033356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600216","BK0191","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621795092","title":"每周股票复盘：浙江医药（600216）股东拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2621795092","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621795092?lang=zh_cn&edition=full","pubTime":"2026-03-22 01:24","pubTimestamp":1774113853,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，浙江医药报收于15.2元，较上周的17.76元下跌14.41%。本周，浙江医药3月16日盘中最高价报18.12元。本周关注点公司公告汇总：股东国投高科计划减持不超过公司总股本的1%公司公告汇总浙江医药股东国投高科技投资有限公司持有公司150,127,573股，占总股本的15.61%。国投高科计划于2026年4月8日至2026年7月7日通过集中竞价交易方式减持不超过9,616,377股，即不超过公司总股本的1%。本次减持不会导致公司控制权变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0191","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619545403","title":"浙江医药最新公告：股东国投高科拟减持不超1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545403","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619545403?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:41","pubTimestamp":1773657668,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，持股5%以上股东国投高科技投资有限公司基于自身经营发展需要，计划于2026年4月8日至2026年7月7日，通过集中竞价交易方式减持不超过961.64万股，占公司总股本的不超过1%；减持股份来源为首次公开发行前持有的股份及由此取得的股票股利。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600028481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600216","BK0028","BK0191","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619127208","title":"每周股票复盘：浙江医药（600216）拟投1.57亿参与生物医药基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2619127208","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619127208?lang=zh_cn&edition=full","pubTime":"2026-03-15 01:36","pubTimestamp":1773509773,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，浙江医药报收于17.76元，较上周的18.38元下跌3.37%。本周，浙江医药3月9日盘中最高价报18.58元，股价触及近一年最高点。浙江医药当前最新总市值170.79亿元，在化学制药板块市值排名30/150，在两市A股市值排名1257/5190。本周关注点公司公告汇总：浙江医药拟出资1.57亿元参与生物医药产业基金投资。公司公告汇总浙江医药股份有限公司与厦门华犇当代创业投资管理有限公司等签署合伙协议，共同投资厦门华犇启航股权投资合伙企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031500000243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","BK0188","600216","BK0028","160635"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618717624","title":"浙江医药（600216）披露与私募基金合作投资公告，3月9日股价下跌4.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618717624","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618717624?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:13","pubTimestamp":1773065599,"startTime":"0","endTime":"0","summary":"截至2026年3月9日收盘，浙江医药报收于17.64元，较前一交易日下跌4.03%，最新总市值为169.63亿元。该股当日开盘18.35元，最高18.58元，最低17.5元，成交额达8.51亿元，换手率为5.0%。近日，浙江医药股份有限公司与厦门华犇当代创业投资管理有限公司等签署合伙协议，共同投资厦门华犇启航股权投资合伙企业。本次交易不构成关联交易或重大资产重组，无需提交董事会或股东会审议。基金尚需完成备案程序，存在投资收益不确定等风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900035098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","600216","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618477306","title":"浙江医药最新公告：以1.57亿元自有资金认缴出资成为厦门华犇启航股权投资合伙企业有限合伙人","url":"https://stock-news.laohu8.com/highlight/detail?id=2618477306","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618477306?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:41","pubTimestamp":1773052884,"startTime":"0","endTime":"0","summary":"浙江医药(600216.SH)公告称，公司与厦门华犇当代创业投资管理有限公司等签署合伙协议，投资厦门华犇启航股权投资合伙企业（有限合伙），认缴出资1.57亿元，占合伙企业认缴出资总额的49.06%。该基金主要聚焦生物医药等战略新兴产业领域，投资比例不低于基金规模的60%。本次交易不构成关联交易，亦不构成重大资产重组。合伙企业可能面临投资项目受多种因素影响导致的不确定性风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900027755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0028","BK0191","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668981","title":"每周股票复盘：浙江医药（600216）新码生物获6.2亿增资并推进ARX305 II期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668981","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668981?lang=zh_cn&edition=full","pubTime":"2026-03-08 01:22","pubTimestamp":1772904131,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，浙江医药报收于18.38元，较上周的16.29元上涨12.83%。本周，浙江医药3月6日盘中最高价报18.54元，股价触及近一年最高点。公司公告汇总：ARX305启动II期临床试验，累计研发投入达1.0965亿元。本次增资后，浙江医药持股比例由45.9186%降至37.6347%，新码生物仍为控股子公司，纳入合并报表范围。浙江医药子公司新码生物启动注射用重组人源化抗CD70单抗-AS269偶联物针对复发/难治性淋巴瘤的II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","BK0191","600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617683866","title":"3月6日浙江医药涨7.86%，长信医疗LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683866","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683866?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:17","pubTimestamp":1772785037,"startTime":"0","endTime":"0","summary":"证券之星消息，3月6日浙江医药涨7.86%创60日新高，收盘报18.38元，换手率6.59%，成交量62.69万手，成交额11.21亿元。重仓浙江医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为长信基金的长信医疗LOF。长信医疗LOF目前规模为1.09亿元，最新净值1.313，较上一交易日上涨1.47%，近一年下跌3.68%。该公募基金现任基金经理为袁婕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600025484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["163001","BK0239","600216","BK0028","BK0188","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617109355","title":"浙江医药（600216）披露ARX305启动II期临床试验公告，3月5日股价上涨0.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617109355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617109355?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:26","pubTimestamp":1772702800,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，浙江医药报收于17.04元，较前一交易日上涨0.77%，最新总市值为163.86亿元。近日，浙江医药披露《关于ARX305启动II期临床试验的公告》。公告显示，公司子公司新码生物已启动注射用重组人源化抗CD70单抗-AS269偶联物针对复发/难治性淋巴瘤的II期临床试验。ARX305为1类生物制品，属创新生物技术药物，用于治疗CD70表达的晚期肿瘤。公司已于2022年启动I期临床试验，目前处于剂量扩组阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500028221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","600216","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617511420","title":"浙江医药(600216.SH)：ARX305启动II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2617511420","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617511420?lang=zh_cn&edition=full","pubTime":"2026-03-05 16:03","pubTimestamp":1772697821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，浙江医药(600216.SH)公告，公司下属子公司浙江新码生物医药股份有限公司(简称“新码生物”)启动注射用重组人源化抗CD70单抗-AS269偶联物(ARX305)针对复发/难治性淋巴瘤的有效性及安全性的单臂、开放II期临床研究。公告显示，注射用重组人源化抗CD70单抗-AS269偶联物(ARX305)是新码生物于2019年10月22日与美国Ambrx公司签署《合作开发和许可协议》合作研发的新一代单克隆抗体偶联药物，用于治疗CD70表达的晚期肿瘤，属于创新生物技术药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600216","BK0028","BK0188","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616334339","title":"浙江医药最新公告：子公司新码生物拟实施C轮增资并引入六名战略投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334339","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616334339?lang=zh_cn&edition=full","pubTime":"2026-03-03 17:43","pubTimestamp":1772531014,"startTime":"0","endTime":"0","summary":"浙江医药公告称，公司下属子公司新码生物拟实施C轮增资并引入六名战略投资者，C轮投资人拟合计以人民币6.21亿元的增资款认购新码生物新增注册资本人民币561万元，取得增资后新码生物合计约16.4018%股权。本次增资完成后，浙江医药直接持有新码生物的股权比例由45.9186%变更为37.6347%，新码生物仍为公司的控股子公司，仍纳入公司的合并报表范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300031503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0191","BK0188","600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843829","title":"每周股票复盘：浙江医药（600216）拟出资2.5亿元参设银发经济基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843829","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843829?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:50","pubTimestamp":1772301020,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，浙江医药报收于16.29元，较上周的16.02元上涨1.69%。本周，浙江医药2月26日盘中最高价报16.71元。浙江医药当前最新总市值156.65亿元，在化学制药板块市值排名34/150，在两市A股市值排名1412/5189。本周关注点公司公告汇总：浙江医药拟出资2.5亿元参与设立银发经济股权投资基金。基金重点投向银发经济及医药大健康领域，存续期限为7年，管理人为中信医疗健康股权投资私募基金管理（北京）有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0191","BK0188","600216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613791683","title":"浙江医药（600216）披露与私募基金合作投资公告，2月24日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613791683?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:32","pubTimestamp":1771925558,"startTime":"0","endTime":"0","summary":"近日，浙江医药股份有限公司披露公告，公司与中信医疗健康股权投资私募基金管理（北京）有限公司等合作方共同投资设立廊坊信慧银发经济股权投资基金合伙企业，基金认缴出资总额为8亿元，公司作为有限合伙人以自有资金认缴出资2.5亿元，占比31.25%。基金重点投向银发经济及医药大健康领域，存续期限为7年，管理人为中信医疗健康股权投资私募基金管理（北京）有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600216","BK0191","BK0188","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778140198664,"stockEarnings":[{"period":"1week","weight":-0.0252},{"period":"1month","weight":-0.0907},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0389},{"period":"1year","weight":0.0897},{"period":"ytd","weight":0.0339}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0722},{"period":"3month","weight":0.0207},{"period":"6month","weight":0.0407},{"period":"1year","weight":0.2545},{"period":"ytd","weight":0.0482}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"51827人(较上一季度减少15.77%)","perCapita":"18357股","listingDate":"1999-10-21","address":"浙江省绍兴市越城区滨海新城致远中大道168号","registeredCapital":"96163万元","survey":" 浙江医药股份有限公司的主营业务是药品与生命营养品的研发、生产和销售以及药品流通。公司的主要产品是维生素、类维生素产品、抗耐药抗生素、抗疟疾类、喹诺酮、抗耐药抗生素、降糖类、激素类、叶黄素、天然维生素E、辅酶Q10、医药商业。公司入选首批浙江省制造业单项冠军企业、浙江省第一批先进级智能工厂。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"浙江医药,600216,浙江医药股票,浙江医药股票老虎,浙江医药股票老虎国际,浙江医药行情,浙江医药股票行情,浙江医药股价,浙江医药股市,浙江医药股票价格,浙江医药股票交易,浙江医药股票购买,浙江医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"浙江医药(600216)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供浙江医药(600216)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}